Stock Price Quote

NATH BIO-GENES (INDIA) LTD.

NSE : NATHBIOGENBSE : 537291ISIN CODE : INE448G01010Industry : AgricultureHouse : Private
BSE164.60-2.7 (-1.61 %)
PREV CLOSE ( ) 167.30
OPEN PRICE ( ) 165.10
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 8856
TODAY'S LOW / HIGH ( )159.00 168.80
52 WK LOW / HIGH ( )159 264.5
NSE163.76-3.37 (-2.02 %)
PREV CLOSE( ) 167.13
OPEN PRICE ( ) 171.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 163.76 (1)
VOLUME 31644
TODAY'S LOW / HIGH( ) 161.55 171.00
52 WK LOW / HIGH ( )161.55 264.31
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 13-09 2000
Management Info
Satish Kagliwal - Chairman Satish Kagliwal - Managing Director
Registered Office

Address Nath House, Nath Road,P B No 318,,
Chhatrapati Sambhajinagar - (Aurangabad),
Maharashtra-431005

Phone 0240-6645555

Email info@nathseeds.com / investor@nathbiogenes.com

Website www.nathbiogenes.com

Registrars Details
Bigshare Services Pvt Ltd
Office No S6-2, 6th Floor, Pinnacle Business Park,Next to Ahura Centre, Mahakali Caves Road,Andheri (E),Mumbai
Listing : BSE, NSE

NEWS

19Oct Nath Bio-Genes (India) submits analyst
Nath Bio-Genes (India) has informed that the Company will hold Earning C..
17Oct Nath Bio-Genes (India) informs about b
Nath Bio-Genes (India) has informed that the meeting of the Board of Dir..
17Aug Nath Bio-Genes (India) informs about o
Nath Bio-Genes (India) has informed that the 31st AGM of the Members of..
17Aug Nath Bio-Genes (India) informs about u
Nath Bio-Genes (India) has informed that Annual General Meeting of the C..
14Jun Nath Bio-Genes (India) informs about l
Nath Bio-Genes (India) has informed that share certificate is reported m..

Financials

in Millions
QTR Dec 24 ANNUAL 24
Net Profit26.54401.770000000001
Gross Profit 37.94 386.740000000001
Operating Profit 79.86510.370000000001
Net Sales 368.733326.25

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Naturite Agro Prod. (BSE)
peergroup  353.20 (1.99%)
M.Cap ( in Cr)187.05
Indo US Bio-Tech (BSE)
peergroup  217.55 (1.42%)
M.Cap ( in Cr)436.23
Genomic Valley (BSE)
peergroup  43.76 (0.60%)
M.Cap ( in Cr)13.37
Beeyu Overseas (BSE)
peergroup  4.44 (2.54%)
M.Cap ( in Cr)6.28
Vrundavan Plantation (BSE)
peergroup  60.00 (-0.05%)
M.Cap ( in Cr)32.00

Shareholding Pattern

NON-INSTITUTION 49.84%
PROMOTERS 45.6%
MUTUAL FUNDS/UTI 4.37%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Nath Bio-Genes (India) Ltd.

Nath Bio-Genes (India) Ltd. was incorporated in the year 2000. Its today's share price is 164.6. Its current market capitalisation stands at Rs 312.81 Cr. In the latest quarter, company has reported Gross Sales of Rs. 3326.25 Cr and Total Income of Rs.3332.78 Cr. The company's management includes Dhiraj Rathi, Ashu Jain, Madhukar Deshpande, Vadla Nagbhushanam, Hitesh Purohit, Jeevanlata Kagliwal, Akash Kagliwal, Satish Kagliwal, Satish Kagliwal.

It is listed on the BSE with a BSE Code of 537291 , NSE with an NSE Symbol of NATHBIOGEN and ISIN of INE448G01010. It's Registered office is at Nath House, Nath Road,P B No 318,Chhatrapati Sambhajinagar - (Aurangabad)-431005, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Ashok R Majethia & Co, Gautam N Associates, Gutam N Associates

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.